Welcome to our dedicated page for Ocean Biomedical news (Ticker: OCEA), a resource for investors and traders seeking the latest updates and insights on Ocean Biomedical stock.
Ocean Biomedical Inc. (OCEA) is a biopharmaceutical innovator developing targeted therapies for oncology, fibrosis, and infectious diseases. This page provides investors and researchers with essential updates on clinical advancements, strategic partnerships, and regulatory milestones.
Access the latest press releases detailing OCEA's progress in immune checkpoint modulation and small molecule therapeutics. Stay informed about developments in bispecific antibody candidates targeting PD-1/CTLA-4 pathways and Chit1-focused fibrosis treatments.
Key updates include clinical trial progress, research collaborations, and scientific publications. Bookmark this page for real-time insights into OCEA's work addressing unmet medical needs through antibody engineering and molecular discovery.
Ocean Biomedical (NASDAQ: OCEA) announced on May 30, 2024, that it received a notice from Nasdaq regarding the late filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2024. The company is currently not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filings with the SEC. This delay follows previous issues with filing its 10-K for the year ended December 31, 2023.
Nasdaq has required Ocean Biomedical to submit a compliance plan by June 14, 2024, and to file the delinquent Form 10-Q by October 14, 2024. The notice has no immediate impact on the listing or trading of Ocean Biomedical's stock, but further delays could affect its Nasdaq listing. The company aims to file the overdue report as soon as possible.
On May 16, 2024, Ocean Biomedical (NASDAQ: OCEA) announced a new patent for malaria therapeutic antibody discoveries by Dr. Jonathan Kurtis. These antibodies aim to prevent malaria infection and treat severe cases by inducing parasite death via apoptosis during a critical stage of the malaria cycle. This patent adds to Ocean Biomedical's global portfolio, particularly important as malaria strains show resistance to current Artemisinin-based treatments. Ocean is optimizing vaccine and therapeutic antibody formulations before IND submission and clinical trials. Malaria remains a leading cause of death, particularly among children, with 627,000 fatalities in 2022. The new patent strengthens Ocean Biomedical's efforts to address this unmet medical need, leveraging partnerships with top research institutions.
FAQ
What is the current stock price of Ocean Biomedical (OCEA)?
What is the market cap of Ocean Biomedical (OCEA)?
